Key facts
- Caldera Therapeutics’s last known valuation is $211.5M (Jan 2026).
- It has raised $112.5M across 1 recorded rounds; the latest was Early Stage VC ($37.5M) in Jan 2026.
- Notable investors include Wellington Management, Omega Funds, Atlas Venture, venBio, Janus Henderson Investors — 7 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Caldera Therapeutics
Funding rounds
1 roundsAbout Caldera Therapeutics
Operator of a clinical-stage biotechnology company intended to develop a bispecific antibody for the treatment of inflammatory bowel disease. The company's system is a clinical-stage bispecific antibody targeting the clinically validated pathways that help to achieve a disease profile with optimized efficacy, safety, pharmacokinetics, and developability, enabling healthcare professionals to provide immunologic and inflammatory disease treatment to patients.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2025
- Website
- calderatx.com/
- Ownership
- Privately Held (backing)
Caldera Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Caldera Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Caldera Therapeutics in its N-PORT filings yet. We sweep new filings monthly.